Leucovorin
- Generic Name
- Leucovorin
- Brand Names
- EnBrace HR, EnLyte, Lederle Leucovorin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23N7O7
- CAS Number
- 58-05-9
- Unique Ingredient Identifier
- Q573I9DVLP
- Background
Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...
- Indication
For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...
- Associated Conditions
- Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
- Associated Therapies
- -
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-10-04
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 7
- Registration Number
- NCT00539617
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement
- Conditions
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 9
- Registration Number
- NCT00537823
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
- Conditions
- Interventions
- First Posted Date
- 2007-09-06
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT00525785
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors
- Conditions
- Interventions
- First Posted Date
- 2007-08-13
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 26
- Registration Number
- NCT00515216
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸Washington University School of Medicine, St. Louis, Missouri, United States
Folfox-B Study for Patients With Colorectal Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT00508872
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin
- Conditions
- Interventions
- First Posted Date
- 2007-07-26
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 63
- Registration Number
- NCT00507585
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination
- Conditions
- Interventions
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 24
- Registration Number
- NCT00507091
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 86
- Registration Number
- NCT00501410
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase I FOLFOX Combination
- Conditions
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 18
- Registration Number
- NCT00499850
- Locations
- 🇦🇺
Research Site, Parkville, Australia
Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC
- Conditions
- Interventions
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2010-08-19
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 330
- Registration Number
- NCT00469443
- Locations
- 🇬🇷
"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
🇬🇷University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.